Short-term local delivery of an inhibitor of ras farnesyltransferase prevents neointima formation in vivo after porcine coronary balloon angioplasty

Circulation

Volumn 104, Issue 13, 2001, Pages 1538-1543

  Work, L M ^a   McPhaden, A R ^a   Pyne, N J ^a   Pyne, S ^a   Wadsworth, R M ^a   Wainwright, C L ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Angioplasty; Arteries; Farnesyl transferase inhibitor; Neointima

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P21;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; HISTOPATHOLOGY; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; SIGNAL TRANSDUCTION; SWINE;

EID: 0035949639     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc3801.095661     Document Type: Article

References (26)

1. The mechanisms of coronary restenosis: Insights from experimental models
2. Growth factors released into the coronary circulation after vascular injury promote proliferation of human vascular smooth muscle cells in culture
3. Multiple growth factors are released from mechanically injured vascular smooth muscle cells
4. Activation of MAP kinase in vivo follows balloon overstretch injury of porcine coronary and carotid arteries
5. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo
6. Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon injured arteries in vivo
7. Farnesyltransferase inhibitors: Preclinical development
8. Manumycin A, inhibitor of ras farnesyltransferase, inhibits proliferation and migration of rat vascular smooth muscle cells
9. Inhibition of human smooth muscle cell proliferation in culture by farnesyl pyrophosphate analogues, inhibitors of in vitro protein: Farnesyl transferase
10. Farnesyltransferase inhibitors: Anti-neoplastic mechanism and clinical prospects
11. Ras farnesylation as a target for novel antitumor agents: Potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase
12. Platelet-derived-growth-factor stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle: Role of pertussis-toxin sensitive G-proteins, c-Src tyrosine kinases and phosphoinositide 3-kinase
13. Sphingosine l-phosphate stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle: Role of endothelial differentiation gene 1, c-Src tyrosine kinase and phosphoinositide 3-kinase
14. Activation of the c-Raf protein kinase by protein kinase C phosphorylation
15. Bradykinin stimulates phospholipase D in primary culture of guinea pig smooth muscle cells
16. q-mediated mitogen activated protein kinase activation
17. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model
18. Recent advances in the study of prenylated proteins
19. Expression of transforming growth factor-β1 is increased in human vascular restenosis lesions
20. Vascular smooth muscle cells from injured rat aortas display elevated matrix production associated with transforming growth factor-β activity
21. RAS farnesyltransferase α subunit in TGF-β and activin signaling
22. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery
23. The kinase inhibitor fasudil (HA-1077) reduces intimal hyperplasia through inhibiting migration and enhancing cell loss of vascular smooth muscle cells
24. Rho and tho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration
25. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries
26. Pathology of in-stent restenosis